The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.